Updated on 2024/11/18

写真a

 
MATSUZAKI Tetsuo
 
Organization
Nagoya University Hospital Department of Hospital Pharmacy Designated assistant professor
Title
Designated assistant professor

Research Areas 3

  1. Life Science / Cell biology

  2. Life Science / Function of nervous system

  3. Life Science / Molecular biology

Research History 3

  1. Nagoya University Hospital   Hospital Pharmacy, Department of Neuropsychopharmacology   Designated assistant professor

    2022.4

  2. Nagoya University Hospital   Hospital Pharmacy

    2019.4 - 2022.3

  3. Japan Society for the Promotion of Science

    2018.4 - 2019.3

Education 2

  1. The University of Tokyo   Graduate School of Pharmaceutical Sciences

    2015.4 - 2019.3

      More details

    Country: Japan

  2. The University of Tokyo   Faculty of Pharmaceutical Sciences   Department of Pharmacy

    2010.4 - 2015.3

      More details

    Country: Japan

Professional Memberships 4

  1. 日本化学療法学会

    2022.1

  2. 日本医療薬学会

    2019.4

  3. 日本病院薬剤師会

    2019.4

  4. 日本分子生物学会

    2014.7

Committee Memberships 3

  1. 一般社団法人東海地区調整機構   実務実習契約・施設概要更新小委員会  

    2024.4   

      More details

    Committee type:Other

  2. 愛知県病院薬剤師会   薬学生病院実習検討委員会  

    2022.4   

      More details

    Committee type:Academic society

  3. 国立研究開発法人日本医療研究開発機構   医薬品等規制調和・評価研究事業「乱用防止に資する医薬品の開発のための製剤学的アプローチ に関する研究」  

    2019.7 - 2022.3   

      More details

    Committee type:Government

Awards 1

  1. 第141回日本薬理学会近畿部会最優秀発表賞

    2022.7   Phosphorylation of twinfilin-1 involved in the reelin signaling plays a crucial role in spine development

    Geyao Dong, Norimichi Itoh, Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Daisuke Mori, Taku Nagai, Toshitaka Nabeshima, Norio Ozaki, Kiyofumi Yamada

 

Papers 10

  1. The Use of Text Mining to Obtain a Historical Overview of Research on Therapeutic Drug Monitoring Reviewed

    Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Kiyofumi Yamada

    Biological and Pharmaceutical Bulletin   Vol. 47 ( 11 ) page: 1883 - 1892   2024.11

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Pharmaceutical Society of Japan  

    <p>Therapeutic drug monitoring (TDM) is a routine clinical practice used to individualize drug dosing to maintain drug efficacy and minimize the consequences of overexposure. TDM is applied to many drug classes, including immunosuppressants, antineoplastic agents, and antibiotics. Considerable effort has been made to establish routine TDM practices for each drug. However, because TDM has been developed within the context of specific drugs, there is insufficient understanding of historical trends within the field of TDM research as a whole. In this study, we employed text-mining approaches to explore trends in the TDM research field. We first performed a PubMed search to determine which drugs and drug classes have been extensively studied in the context of TDM. This investigation revealed that the most commonly studied drugs are tacrolimus, followed by cyclosporine and vancomycin. With regard to drug classes, most studies focused on immunosuppressants, antibiotics, and antineoplastic agents. We also subjected PubMed records of TDM-related studies to a series of text-mining pipelines. Our analyses revealed how TDM research has evolved over the years, thereby serving as a cornerstone for forecasting future research trends.</p>

    DOI: 10.1248/bpb.b24-00319

    PubMed

    CiNii Research

  2. A novel plasmid‐based experimental system in <i>Saccharomyces cerevisiae</i> that enables the introduction of 10 different plasmids into cells Reviewed

    Geyao Dong, Tsuyoshi Nakai, Tetsuo Matsuzaki

    FEBS Open Bio     2024.10

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    The budding yeast Saccharomyces cerevisiae is commonly used as an expression platform for the production of valuable compounds. Yeast‐based genetic research can uniquely utilize auxotrophy in transformant selection: auxotrophic complementation by an auxotrophic marker gene on exogenous DNA (such as plasmids). However, the number of required auxotrophic nutrients restricts the number of plasmids maintained by the cells. We, therefore, developed novel Δ10 strains that are auxotrophic for 10 different nutrients and new plasmids with two multiple cloning sites and auxotrophic markers for use in Δ10 strains. We confirmed that Δ10 strains were able to maintain 10 types of plasmids. Using plasmids encoding model proteins, we detected the co‐expression of 17 different genes in Δ10 cell lines. We also constructed Δ9 strains that exhibited auxotrophy for nine nutrients and increased growth compared to Δ10. This study opens a new avenue for the co‐expression of a large number of genes in eukaryotic cells.

    DOI: 10.1002/2211-5463.13893

    Web of Science

    Scopus

    PubMed

  3. Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia

    Rinako Tanaka, Jingzhu Liao, Yue Liu, Wenjun Zhu, Kisa Fukuzawa, Masamichi Kondo, Masahito Sawahata, Daisuke Mori, Akihiro Mouri, Hisayoshi Kubota, Daiki Tachibana, Yohei Kobayashi, Tetsuo Matsuzaki, Taku Nagai, Toshitaka Nabeshima, Kozo Kaibuchi, Norio Ozaki, Hiroyuki Mizoguchi, Kiyofumi Yamada

        2024.9

     More details

    Language:English   Publisher:Cold Spring Harbor Laboratory  

    1Abstract

    Copy number variations in theARHGAP10gene encoding Rho GTPase–activating protein 10 are significantly associated with schizophrenia. ARHGAP10 negatively regulates RhoA/Rho-kinase (ROCK) signaling. We previously demonstrated that fasudil, a non-selective ROCK inhibitor, exhibited antipsychotic-like effects in several mouse models of schizophrenia. ROCK has two subtypes, ROCK1 and ROCK2. ROCK1 is mainly expressed in the thymus and blood, while ROCK2 is predominantly expressed in the brain. Therefore, it is expected that like fasudil, selective ROCK2 inhibitors will exhibit antipsychotic-like effects, accompanied by a lower incidence of adverse effects due to ROCK1 inhibition. Here, we used genetic and pharmacological models of schizophrenia to investigate whether the selective ROCK2 inhibitor KD025 would show antipsychotic-like effects with a favorable adverse effect profile. Oral administration of KD025 suppressed the abnormal increase in the phosphorylation level of myosin phosphatase–targeting subunit 1, a substrate of ROCK, and ameliorated the decreased spine density of layer 2/3 pyramidal neurons in the medial prefrontal cortex ofArhgap10S490P/NHEJ mice. Furthermore, KD025 mitigated the methamphetamine-induced impairment of visual discrimination (VD) inArhgap10S490P/NHEJ and wild-type mice. KD025 also reduced MK-801–induced impairments of VD, novel object recognition, and hyperlocomotion. Regarding side effects that are commonly seen with typical antipsychotics, KD025 did not affect systolic blood pressure and did not induce extrapyramidal symptoms, hyperprolactinemia, or hyperglycemia at the effective dosage in naïve wild-type mice. Taken together, KD025 shows antipsychotic-like effects with a favorable adverse effect profile in genetic and pharmacological mouse models of schizophrenia.

    DOI: 10.1101/2024.09.16.613372

  4. Integration of pharmacists' knowledge into a predictive model for teicoplanin dose planning

    Tetsuo Matsuzaki, Tsuyoshi Nakai, Yoshiaki Kato, Kiyofumi Yamada, Tetsuya Yagi

        2023.12

     More details

    Publisher:Cold Spring Harbor Laboratory  

    Teicoplanin is an important antimicrobial agent for methicillin-resistant Staphylococcus aureus infections. To enhance its clinical effectiveness while preventing adverse effects, therapeutic drug monitoring (TDM) of teicoplanin trough concentration is recommended. Given the importance of the early achievement of therapeutic concentrations for treatment success, initial dosing regimens are deliberately designed based on patient information. Considerable effort has been dedicated to developing an optimal initial dose plan for specific populations; however, comprehensive strategies for tailoring teicoplanin dosing have not been successfully implemented. The initial dose planning of teicoplanin is conducted at the clinician's discretion and is thus strongly dependent on the clinician's experience and expertise. The present study aimed to use a machine learning (ML) approach to integrate clinicians' knowledge into a predictive model for initial teicoplanin dose planning. We first confirmed that dose planning by pharmacists dedicated to TDM (hereafter TDM pharmacists) significantly improved early therapeutic target attainment for patients without an intensive care unit or high care unit stay, providing the first evidence that dose planning of teicoplanin by experienced clinicians enhances early teicoplanin therapeutic exposure. Next, we used a dataset of teicoplanin initial dose planning by TDM pharmacists to train and implement the model, yielding a model that emulated TDM pharmacists' decision-making for dosing. We further applied ML to cases without TDM pharmacist dose planning and found that the target attainment rate of the initial teicoplanin concentration markedly increased. Our study opens a new avenue for tailoring the initial dosing regimens of teicoplanin using a TDM pharmacist-trained ML system.

    DOI: 10.1101/2023.12.14.23299934

  5. Overview of draft guidelines for the development of abuse-deterrent opioid formulations Reviewed

      Vol. 58 ( 2 ) page: 51 - 57   2023.12

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  6. Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene Reviewed

    Rinako Tanaka, Jingzhu Liao, Kazuhiro Hada, Daisuke Mori, Taku Nagai, Tetsuo Matsuzaki, Toshitaka Nabeshima, Kozo Kaibuchi, Norio Ozaki, Hiroyuki Mizoguchi, Kiyofumi Yamada

    Pharmacological Research   Vol. 187   page: 106589 - 106589   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    Copy-number variations in the ARHGAP10 gene encoding Rho GTPase-activating protein 10 are associated with schizophrenia. Model mice (Arhgap10 S490P/NHEJ mice) that carry "double-hit" mutations in the Arhgap10 gene mimic the schizophrenia in a Japanese patient, exhibiting altered spine density, methamphetamine-induced cognitive dysfunction, and activation of RhoA/Rho-kinase signaling. However, it remains unclear whether the activation of RhoA/Rho-kinase signaling due to schizophrenia-associated Arhgap10 mutations causes the phe-notypes of these model mice. Here, we investigated the effects of fasudil, a brain permeable Rho-kinase inhibitor, on altered spine density in the medial prefrontal cortex (mPFC) and on methamphetamine-induced cognitive impairment in a touchscreen-based visual discrimination task in Arhgap10 S490P/NHEJ mice. Fasudil (20 mg/ kg, intraperitoneal) suppressed the increased phosphorylation of myosin phosphatase-targeting subunit 1, a substrate of Rho-kinase, in the striatum and mPFC of Arhgap10 S490P/NHEJ mice. In addition, daily oral administration of fasudil (20 mg/kg/day) for 7 days ameliorated the reduced spine density of layer 2/3 pyra-midal neurons in the mPFC. Moreover, fasudil (3-20 mg/kg, intraperitoneal) rescued the methamphetamine (0.3 mg/kg)-induced cognitive impairment of visual discrimination in Arhgap10 S490P/NHEJ mice. Our results suggest that Rho-kinase plays significant roles in the neuropathological changes in spine morphology and in the vulnerability of cognition to methamphetamine in mice with schizophrenia-associated Arhgap10 mutations.

    DOI: 10.1016/j.phrs.2022.106589

    Web of Science

    Scopus

    PubMed

  7. Fasudil ameliorates methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated gene mutations in the Arhgap10 gene

    Tetsuo Matsuzaki

    British Journal of Pharmacology   Vol. 180   page: 1004 - 1004   2023

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  8. A machine learning model that emulates experts’ decision making in vancomycin initial dose planning Reviewed

    Tetsuo Matsuzaki, Yoshiaki Kato, Hiroyuki Mizoguchi, Kiyofumi Yamada

    Journal of Pharmacological Sciences   Vol. 148 ( 4 ) page: 358 - 363   2022.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.jphs.2022.02.005

    Web of Science

    Scopus

    PubMed

  9. The ubiquitination-deubiquitination cycle on the ribosomal protein eS7A is crucial for efficient translation Reviewed

    Yuka Takehara, Hideki Yashiroda, Yoshitaka Matsuo, Xian Zhao, Akane Kamigaki, Tetsuo Matsuzaki, Hidetaka Kosako, Toshifumi Inada, Shigeo Murata

    iScience   Vol. 24 ( 3 ) page: 102145 - 102145   2021.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.isci.2021.102145

    Web of Science

  10. The review system for abuse deterrent opioid formulations in the United States Reviewed

    Tetsuo Matsuzaki, Hiroki Okumura, Taku Nagai, Kiyofumi Yamada

      Vol. 56 ( 2 )   2021

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

MISC 1

  1. AIと薬剤師業務 Invited

    松﨑 哲郎

    日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists   Vol. 60 ( 6 ) page: 573 - 577   2024.6

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (other)   Publisher:東京 : 日本病院薬剤師会  

    CiNii Books

    Other Link: https://ndlsearch.ndl.go.jp/books/R000000004-I033556583

Presentations 30

  1. 多種類遺伝子発現を実現する新規出芽酵母実験系の樹立とその改良

    松﨑 哲郎, Geyao Dong, 中井剛

    日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2024  2024.10.27 

     More details

    Event date: 2024.10

    Presentation type:Oral presentation (general)  

  2. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    松﨑 哲郎, Geyao Dong, 中井 剛

    日本薬学会第144年会  2024.3.30 

     More details

    Event date: 2024.3

    Language:Japanese   Presentation type:Oral presentation (general)  

  3. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    松﨑 哲郎, Geyao Dong, 中井 剛

    日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2023  2023.11.12 

     More details

    Event date: 2023.11

    Presentation type:Oral presentation (general)  

  4. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    Geyao Dong, 中井剛, 松﨑哲郎

    第69回 日本薬学会東海支部大会  2023.7.8 

     More details

    Event date: 2023.7

    Language:Japanese   Presentation type:Oral presentation (general)  

  5. Comprehensive Phosphoproteomic Analysis In Reelin Mutant Mice Identified A Crucial Role Of Twinfilin1 In Spine Development And Actin Dynamics.

    GY. Dong, N. Itoh, T. Matsui, A. Sato, T. Matsuzaki, H. Mizoguchi, D. Mori, T. Nagai, T. Nabeshima, N. Ozaki, K. Yamada

    34th CINP World Congress of Neuropsychopharmacology 

     More details

    Event date: 2023.5

    Language:English   Presentation type:Poster presentation  

  6. Twinfilin1 Phosphorylation Is Crucial For Reelin Signaling In The Regulation Of Spine Morphology And Cognitive Function.

    K. Yamada, G. Dong, N. Itoh, T. Matsui, A. Sato, T. Matsuzaki, H. Mizoguchi, D. Mori, T. Nagai, T. Nabeshima, N. Ozaki

    34th CINP World Congress of Neuropsychopharmacology 

     More details

    Event date: 2023.5

    Language:English   Presentation type:Poster presentation  

  7. Phosphorylation of twinfilin-1 involved in the reelin signaling plays a crucial role in spine development Invited

    Geyao Dong, Norimichi Itoh, Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Daisuke Mori, Taku Nagai, Toshitaka Nabeshima, Norio Ozaki, Kiyofumi Yamada

    第96回日本薬理学会年会  2022.11.30 

     More details

    Event date: 2022.11 - 2022.12

    Presentation type:Oral presentation (invited, special)  

  8. 薬学実務実習生の名古屋大学医学部附属病院における多職種連携の認識 Invited

    吉見陽, 等浩太郎, 白松貴子, 松崎哲郎, 千﨑康司, 山田清文, 野田幸裕

    第15回日本保健医療福祉連携教育学会学術集会  2022.11.13 

     More details

    Event date: 2022.11

    Presentation type:Oral presentation (invited, special)  

  9. Phosphorylated twinfilin1 plays a major role in dendritic spine development, but not brain layer formation

    Geyao Dong, Norimichi Itoh, Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Daisuke Mori, Taku Nagai, Toshitaka Nabeshima, Norio Ozaki, Kiyofumi Yamada

    BPCNPNPPP4学会合同年会  2022.11.4 

     More details

    Event date: 2022.11

    Presentation type:Poster presentation  

  10. Gemcitabine + nab-paclitaxel (GnP) 療法による 好中球減少症が切除不能膵癌患者の予後に 与える影響について

    長岡侑里, 今俊介, 松﨑哲郎, 溝口博之, 山田清文

    第32回日本医療薬学会年会  2022.9.23 

     More details

    Event date: 2022.9

    Presentation type:Poster presentation  

  11. アメリカにおける医療用麻薬乱用防止製剤の審査 Invited

    松﨑哲郎, 永井拓, 山田清文

    2022年度アルコール・薬物依存症関連学会合同学術総会  2022.9.10 

     More details

    Event date: 2022.9

    Presentation type:Oral presentation (invited, special)  

  12. Phosphorylation of twinfilin-1 involved in the reelin signaling plays a crucial role in spine development

    Geyao Dong, Norimichi Itoh, Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Daisuke Mori, Taku Nagai, Toshitaka Nabeshima, Norio Ozaki, Kiyofumi Yamada

    2022.7.1 

     More details

    Event date: 2022.7

    Presentation type:Oral presentation (general)  

  13. 専門家知識を組み入れたバンコマイシン初期投与設計用人工知能アプリケーションの樹立

    松﨑哲郎, 加藤善章, 溝口博之, 山田清文

    第5回フレッシャーズ・カンファレンス  2022.6.12 

     More details

    Event date: 2022.6

    Presentation type:Oral presentation (general)  

  14. 医薬品副作用データベース(JADER)を用いた高齢者における抗微生物薬の安全性の検討

    加藤 善章, 北川 佳奈子, 井口 光孝, 岡 圭輔, 松崎 哲郎, 八木 哲也, 山田 清文

    第70回日本化学療法学会総会  2022.6.5 

     More details

    Event date: 2022.6

    Presentation type:Oral presentation (general)  

  15. 当院におけるE. cloacae complex菌血症例に対する治療の検討

    岡 圭輔, 森岡 悠, 井口 光孝, 矢田 吉城, 松崎 哲郎, 北川 佳奈子, 加藤 善章, 八木 哲也

    第70回日本化学療法学会総会  2022.6.4 

     More details

    Event date: 2022.6

    Presentation type:Oral presentation (general)  

  16. 専門家知識を組み入れたバンコマイシン初期投与設計用人工知能アプリケーションの樹立

    松﨑哲郎、加藤善章、溝口博之、山田清文

    第70回日本化学療法学会総会  2022.6.5 

     More details

    Event date: 2022.6

    Presentation type:Oral presentation (general)  

  17. A machine learning model that emulates experts' decision making in vancomycin initial dose planning

    Tetsuo Matsuzaki, Yoshiaki Kato, Hiroyuki Mizoguchi, Kiyofumi Yamada

    Asian Conference on Clinical Pharmacy 2022  2022.2.11 

     More details

    Event date: 2022.2

    Presentation type:Poster presentation  

  18. 病院薬剤師から見た 薬剤師/博士号の意義 Invited

    松﨑 哲郎

    令和3年度第1回「国公立大学高度薬学人材育成ワークショップ」 

     More details

    Event date: 2021.9

    Presentation type:Symposium, workshop panel (nominated)  

  19. アメリカにおける医療用麻薬乱用防止製剤の審査に関する調査

    松﨑哲郎, 奥村啓樹, 永井拓, 山田清文

    第55回アルコール・アディクション医学会学術総会  2020.11.23 

     More details

    Event date: 2020.11

    Presentation type:Oral presentation (general)  

  20. アメリカにおける医療用麻薬乱用防止製剤の審査に関する調査

    松﨑哲郎, 奥村啓樹, 永井拓, 山田清文

    第30回日本医療薬学会年会  2020.10.24 

     More details

    Event date: 2020.10 - 2020.11

    Presentation type:Poster presentation  

  21. 出芽酵母を用いた哺乳類のプロテアソーム20S core particle再構成

    石原 慧, 松崎 哲郎, 八代田 英樹, 村田 茂穂

    第41回日本分子生物学会年会  2018.11.30 

     More details

    Event date: 2018.11

    Language:English   Presentation type:Poster presentation  

  22. アミロイド形成タンパク質が細胞内で毒性を生む要因の探究

    Cai Xiochen, 松崎 哲郎, 平山 尚志郎, 八代田 英樹, 村田 茂穂

    2017年度生命科学系合同年次大会  2017.12.7 

     More details

    Event date: 2017.12

    Language:English   Presentation type:Poster presentation  

  23. eIF6/Tif6のプロテアソーム形成への関与

    八代田 英樹, 松崎 哲郎, 村田 茂穂

    第191回酵母細胞研究会例会  2016.11.11 

     More details

    Event date: 2016.11

    Presentation type:Oral presentation (general)  

  24. 出芽酵母を用いたアミロイド形成タンパク質が毒性を発揮する仕組みの解明

    八代田 英樹, Cai Xiochen, 松崎 哲郎, 村田 茂穂

    第89回日本生化学大会  2016.9.26 

     More details

    Event date: 2016.9

    Presentation type:Oral presentation (general)  

  25. Eukaryotic initiation factor 6 (eIF6) is involved in the assembly of the proteasome core particle

    Tetsuo Matsuzaki, Hideki Yashiroda, Shigeo Murata

    第16回東京大学生命科学シンポジウム  2016.4.23 

     More details

    Event date: 2016.4

    Presentation type:Poster presentation  

  26. Eukaryotic initiation factor 6 (eIF6) is involved in the assembly of the proteasome core particle

    Cold Spring Harbor Asia, Ubiquitin Family, Autophagy, and Diseases  2016.4.20 

     More details

    Event date: 2016.4

    Language:English   Presentation type:Poster presentation  

  27. Exploring modulators of the toxicity by amyloidogenic proteins

    Cai Xiaochen, Tetsuo Matsuzaki, Hideki Yashiroda, Shigeo Murata

    Cold Spring Harbor Asia Ubiquitin Family Autophagy and Diseases  2016.4.20 

     More details

    Event date: 2016.4

    Presentation type:Poster presentation  

  28. Reconstitution of the mouse proteasome core particle in yeast

    2015.12.16 

     More details

    Event date: 2015.12

    Presentation type:Poster presentation  

  29. 翻訳開始因子eIF6/Tif6は正常なプロテアソーム機能に必要である

    松崎哲郎, 八代田英樹, 村田茂穂

    第48回酵母遺伝学フォーラム研究報告会  2015.9.2 

     More details

    Event date: 2015.8 - 2015.9

    Presentation type:Oral presentation (general)  

  30. 出芽酵母60Sリボソーム生合成因子TIF6はプロテアソーム形成に関与する

    松崎哲郎, 八代田英樹, 村田茂穂

    第37回日本分子生物学会年会  2014.11.25 

     More details

    Event date: 2014.11

    Presentation type:Poster presentation  

▼display all

Other research activities 2

  1. 一般社団法人日本病院薬剤師会 病院薬学認定薬剤師

    2024.7

  2. 一般社団法人薬学教育協議会 認定実務実習指導薬剤師

    2024.4

KAKENHI (Grants-in-Aid for Scientific Research) 6

  1. バイオマスからの有用化学物質産生に資する出芽酵母多種類遺伝子発現系の構築

    Grant number:24K17995  2024.4 - 2026.3

    日本学術振興会  科学研究費助成事業  若手研究

    松崎 哲郎

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  2. 専門家知識を組み込んだ抗MRSA薬初期投与設計用人工知能の構築

    2024.4 - 2025.3

    一般財団法人 中京長寿医療研究推進財団  令和5年度医学研究助成 

    松﨑 哲郎

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\300000 ( Direct Cost: \300000 )

  3. 出芽酵母新規タンパク質発現系を応用した抗生剤生合成経路の樹立

    2023.9 - 2024.8

    公益財団法人 杜の都医学振興財団  2023年度 研究助成金 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\500000 ( Direct Cost: \500000 )

  4. Study on the regulation mechanism of neural spine morphology and cognitive function by twinfilin-1

    Grant number:23H02669  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Coinvestigator(s) 

  5. 令和3年度AI活用臨床研究助成

    2022.4 - 2023.3

    東海国立大学機構 医療健康データ統合研究教育拠点 (C-HiT) 

    松﨑 哲郎

      More details

    Authorship:Principal investigator 

  6. プロテアソーム活性が寿命を変化させる分子機構の解明

    Grant number:18J13822  2018.4 - 2019.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for JSPS Fellows  Grant-in-Aid for JSPS Fellows

▼display all

 

Teaching Experience (Off-campus) 3

  1. Pharmacy clinical training program (hospital)

    2022.4 Nagoya University Hospital)

  2. ベーシックトレーニング (名古屋大学大学院医学系研究科)

    2022.4

  3. 基礎医学セミナー (名古屋大学医学部)

    2022.4